BlueWind RENOVA iStim™ System for the Treatment of OAB (OASIS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03596671 |
Recruitment Status :
Recruiting
First Posted : July 24, 2018
Last Update Posted : January 3, 2024
|
Sponsor:
BlueWind Medical
Information provided by (Responsible Party):
BlueWind Medical
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 1, 2018 | ||||||
First Posted Date ICMJE | July 24, 2018 | ||||||
Last Update Posted Date | January 3, 2024 | ||||||
Actual Study Start Date ICMJE | June 12, 2019 | ||||||
Actual Primary Completion Date | October 28, 2022 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | BlueWind RENOVA iStim™ System for the Treatment of OAB | ||||||
Official Title ICMJE | A Prospective Study to Assess the Efficacy and Safety of the BlueWind RENOVA iStim™ System in the Treatment of Patients Diagnosed With Overactive Bladder (OASIS - OverActive Bladder StImulation System Study) | ||||||
Brief Summary | The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Not Applicable | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||
Condition ICMJE | Treatment of Patients Suffering From Overactive Bladder (OAB) | ||||||
Intervention ICMJE | Device: RENOVA iStim™ System
Tibial implantable neuromodulation device
|
||||||
Study Arms ICMJE | Experimental: Treatment arm
RENOVA iStim™ System implanted patients
Intervention: Device: RENOVA iStim™ System
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE |
200 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | January 2025 | ||||||
Actual Primary Completion Date | October 28, 2022 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years to 80 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
|
||||||
Listed Location Countries ICMJE | Belgium, Netherlands, United Kingdom, United States | ||||||
Removed Location Countries | Germany, Israel | ||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03596671 | ||||||
Other Study ID Numbers ICMJE | G02-CLP-0002 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Current Responsible Party | BlueWind Medical | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | BlueWind Medical | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
|
||||||
PRS Account | BlueWind Medical | ||||||
Verification Date | December 2023 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |